AI Investment Decisions in Life Sciences with Daniel Buchta, Head of Investor Relations, Lonza
AI Investment Decisions in Life Sciences: A curated executive roundtable in Basel.
A private, off-the-record exchange among senior leaders from pharma, biotech and medtech on how AI investment decisions are actually made at the executive level.
Guest of honour Daniel Buchta, Head of Investor Relations, Lonza.
The table is deliberately small: 8 to 12 participants, so the conversation stays candid and the room stays useful. A light aperitivo with a selection of finger food will be served during the evening.
The question on the table If you had to justify a major AI investment today, how would you frame the decision?
We will look at how leaders weigh strategic priorities and risk, from sustaining current performance to accelerating future launches. We will also cover the choice to build, buy or partner, including a newer option: investing directly in the AI startup ecosystem. What does that mean inside a regulated industry? Where do the real tradeoffs sit, and which models suit R&D, Commercial Ops or Tech Ops?
Who is at the table CEOs and C-level executives (CTO, CIO, CDO), VPs and board members from leading life sciences companies across Switzerland.
When Monday, 26 October 2026, 18:00 – 19:30
Where A central venue in Basel Stadt. The exact address is shared on confirmation.
How to join This is a ticketed event with curated participants. Every registration is reviewed and validated before confirmation. This keeps the table balanced and makes the conversation meaningful for everyone who takes part. Places are kept few to protect the quality of the exchange and the trust among those at the table.
Questions: info@techlounges.com
Organized by TechLounges Association, Basel.